search
Back to results

Antidepressant Effects of Nitrous Oxide

Primary Purpose

Major Depressive Disorder, Treatment Resistant Depression

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Nitrous oxide gas for inhalation
Placebo
Sponsored by
University of Chicago
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Major Depressive Disorder focused on measuring Depression, Antidepressant, Nitrous Oxide

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Adult (≥18 years, both sexes)
  2. DSM-5 criteria for MDD without psychosis, as determined using a structured clinical interview [Mini International Neuropsychiatric Interview], MDD, defined by a pre-treatment score >16 on the HDRS-21 scale and meeting DSM-5 for MDD

Exclusion Criteria:

  1. A current or past history of bipolar disorder, schizophrenia, or schizoaffective disorder.
  2. Current obsessive-compulsive disorder, panic disorder, or documented Axis II diagnoses
  3. Active suicidal intention, as determined by clinical interview assessment tool (Sheehan-STS) and clinical examination
  4. Active or recent (<12 months) substance use disorder; excluding nicotine
  5. Administration of NMDA-antagonists (e.g., ketamine) in previous 3 months
  6. Ongoing treatment with ECT
  7. Presence of acute medical illness that could interfere with study participation, including significant pulmonary disease
  8. Pregnancy or breastfeeding
  9. Any contraindications to the use of nitrous oxide (e.g., pneumothorax, middle ear occlusion, elevated intracranial pressure, chronic cobalamin or folate deficiency unless treated with folic acid or vitamin B12).

Sites / Locations

  • University of Chicago MedicineRecruiting
  • The Alfred HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Treatment; Nitrous Oxide 50% or 25%, group

Control; Oxygen-air mixture, group

Arm Description

Four-weekly, 60-minute inhalation sessions of 25% or 50% nitrous oxide, randomly assigned.

Four-weekly, 60-minute inhalation sessions of an oxygen and air mixture.

Outcomes

Primary Outcome Measures

Change in HDRS-21 score
Monitor changes in Hamilton Depression Rating Scale-21 (HDRS-21) scores to determine whether a series of four, 60-minute sessions of inhaled nitrous oxide vs placebo (once-per-week) has significant antidepressant activity. The HDRS-21 is an interview-based psychiatric diagnostic used to evaluate depression severity. Scores are calculated by using the first 17 responses of this 21 item questionnaire. Higher scores are associated with more severe depression: 0 - 7 = Normal 8 - 13 = Mild Depression 14-18 = Moderate Depression 19 - 22 = Severe Depression > 23 = Very Severe Depression Max score = 52

Secondary Outcome Measures

Treatment response
Treatment response (≥50% reduction on HDRS-21) to nitrous oxide vs placebo will be measured.
Changes in 'Profile of Mood States' scores
Monitoring daily mood changes using the Profile of Mood States (POMS) a validated 'self-report' psychological diagnostic containing 65 emotions or 'mood states' to determine the pattern of treatment response Patients rank their current mood states using a scale of 'not-at-all', 'a-little', 'moderately', 'quite-a-lot', 'extremely'. Responses are scored to calculated the Total Mood Disturbance (TMD): TMD = (tension + depression + anger + fatigue + confusion) - Vigor
Sustainability of treatment response
Determine sustained response and remission following study treatments (nitrous vs placebo) using Hamilton Depression Rating Scale-21 (HDRS-21) score. The HDRS-21 is an interview-based psychiatric diagnostic used to evaluate depression severity. Scores are calculated by using the first 17 responses of this 21 item questionnaire. Higher scores are associated with more severe depression: 0 - 7 = Normal 8 - 13 = Mild Depression 14-18 = Moderate Depression 19 - 22 = Severe Depression > 23 = Very Severe Depression Max score = 52
Treatment dose response comparison
Compare dose response of 25% vs 50% nitrous oxide to establish whether the concentration is related to outcome. Determined with treatment-by-dose (group) interaction term in a logistic regression model to assess for statistical significance.
Treatment cycle compliance
Evaluate compliance to complete 4-cycle inhalation treatments of nitrous oxide vs placebo. Determined by ability, inability, or refusal to receive all 4-treatments of randomized inhalation sessions (nitrous oxide vs placebo).
Changes in Computerize Adaptive Testing - Mental Health (CAT-MH) 'depression' scores
This CAT-MH is a validated self-reporting diagnostic that adaptively selects a small optimal set of items from a large bank of approximately 1,500 items, targeted to individuals current or historical level of severity and likelihood of 'depression'. Generated scores include severity and liklihood percentile: - depression = (%) normal, mild, moderate, severe
Changes in Computerize Adaptive Testing - Mental Health (CAT-MH) 'anxiety' scores
This CAT-MH is a validated self-reporting diagnostic that adaptively selects a small optimal set of items from a large bank of approximately 1,500 items, targeted to individuals current or historical level of severity and likelihood of 'anxiety'. Generated scores include severity and liklihood percentile: - anxiety = (%) normal, mild, moderate, severe
Changes in Computerize Adaptive Testing - Mental Health (CAT-MH) 'suicide' scores
This CAT-MH is a validated self-reporting diagnostic that adaptively selects a small optimal set of items from a large bank of approximately 1,500 items, targeted to individuals current or historical level of severity and likelihood of 'suicide'. Generated scores include severity and liklihood percentile: - suicide = (%) low, intermediate, high
Suicidal ideation tracking
Suicidal ideation will be be tracked using the Sheehan Suicidality Tracking Scale (S-STS), a validated self-report diagnostic tool designed to assess and monitor suicidality. The standard S-STS consists of 14 core questions related to suicidality phenomena and is designed for use in clinical research studies and in clinical settings. Scores are summed based on individual responses 'not-at-all = 0', 'a little = 1', 'moderately = 2', 'very = 3', 'extremely = 4', to generate a summated score (total score), individual factor scores for suicidal ideation, suicidal intent, suicidal planning, suicidal behavior, and non-suicidal self-injury. All results are monitored in real time by a trained psychiatry (MD) rater.
Visual Analog Scale (VAS)
The VAS is a unidimensional measure of pain intensity and use in the field of psychology to measure 'well-being'. Patients mark on a line the point that they feel represents their perception of their current state, with the score determined by measuring in millimetres from the left hand end of the line to the point that the patient marks. The range of score from 0-100 mm and represent: no pain (0-4 mm), mild pain(5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm).
Treatment remission
Treatment remission (HDRS-21 ≤7 points) to nitrous oxide vs. placebo will be measured.

Full Information

First Posted
November 9, 2021
Last Updated
December 21, 2022
Sponsor
University of Chicago
Collaborators
The Alfred
search

1. Study Identification

Unique Protocol Identification Number
NCT05357040
Brief Title
Antidepressant Effects of Nitrous Oxide
Official Title
Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 30, 2021 (Actual)
Primary Completion Date
February 1, 2024 (Anticipated)
Study Completion Date
April 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Chicago
Collaborators
The Alfred

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and to plan a future large pragmatic trial.
Detailed Description
The investigators are conducting a randomized controlled trial to evaluate the antidepressant effects of nitrous oxide in people with Major Depressive Disorder (MDD). MDD is a global medical condition that causes significant health and economic burden. Recent studies have shown that a single dose of ketamine, an NMDA-antagonist, has fast and long lasting anti-depressant effect. Nitrous oxide, another NMDA-antagonist, is widely used for anesthesia and analgesia, safer to administer and has fewer side effects than ketamine. A randomized controlled crossover feasibility study showed significant reduction in depressive symptoms at 2 and 24 hours after a single 1-hour treatment session of inhaled nitrous oxide compared with placebo. Nitrous oxide is inexpensive and can be safely administered by any trained clinician. If found to be efficacious, it could be used to provide rapid anti-depressant effect whilst the benefit of traditional anti-depressants has its delayed effect. Another potential application could be in acutely suicidal patients. This trial will enable confirmation and extension of the findings from the feasibility study, and identify the optimal dose and regimen in a broader population of those with MDD. Participants will be randomized to receive a weekly 1-hour inhalational session of either nitrous oxide or placebo (oxygen-air mixture) for 4 weeks, and the nitrous group will be further randomly assigned to a dose of 50% or 25% nitrous oxide. Depression severity and outcomes related to treatment responses will be continuously assessed by a 'blinded-to-randomization' psychiatry (MD) rater at weekly intervals during study patient participation, using validated psychiatric diagnostics (Hamilton Depression Rating Scale-21 [HDRS-21 or HAM-D]; Profile of Mood States [POMS]; Computerized Adaptive Test-Mental Health [CAT-MH]; Sheehan-STS [S-STS]; Visual Analog Scale [VAS]).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depressive Disorder, Treatment Resistant Depression
Keywords
Depression, Antidepressant, Nitrous Oxide

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Parallel-group, controlled trial; randomized participants (1:1) to nitrous oxide (Nitrous group) or oxygen-air mixture (FiO2 ≈0.3, Control group). The Nitrous group will be further randomly assigned to either 50% nitrous oxide in oxygen (FiO2 0.5) or 25% nitrous oxide in oxygen (FiO2 0.75).
Masking
ParticipantOutcomes Assessor
Masking Description
Patient and assessor blinded to study group assigned.
Allocation
Randomized
Enrollment
172 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment; Nitrous Oxide 50% or 25%, group
Arm Type
Active Comparator
Arm Description
Four-weekly, 60-minute inhalation sessions of 25% or 50% nitrous oxide, randomly assigned.
Arm Title
Control; Oxygen-air mixture, group
Arm Type
Placebo Comparator
Arm Description
Four-weekly, 60-minute inhalation sessions of an oxygen and air mixture.
Intervention Type
Drug
Intervention Name(s)
Nitrous oxide gas for inhalation
Other Intervention Name(s)
N2O, Laughing gas, Nitrous Oxide, Nitrous
Intervention Description
60-minute sessions of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) or 25% nitrous oxide in oxygen (FiO2 0.75), administered weekly for 4-weeks. Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
60-minute sessions of inhaled oxygen-air mixture (FiO2 ≈0.3) to be administered weekly for 4-weeks. Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Primary Outcome Measure Information:
Title
Change in HDRS-21 score
Description
Monitor changes in Hamilton Depression Rating Scale-21 (HDRS-21) scores to determine whether a series of four, 60-minute sessions of inhaled nitrous oxide vs placebo (once-per-week) has significant antidepressant activity. The HDRS-21 is an interview-based psychiatric diagnostic used to evaluate depression severity. Scores are calculated by using the first 17 responses of this 21 item questionnaire. Higher scores are associated with more severe depression: 0 - 7 = Normal 8 - 13 = Mild Depression 14-18 = Moderate Depression 19 - 22 = Severe Depression > 23 = Very Severe Depression Max score = 52
Time Frame
Over 4-weeks from baseline
Secondary Outcome Measure Information:
Title
Treatment response
Description
Treatment response (≥50% reduction on HDRS-21) to nitrous oxide vs placebo will be measured.
Time Frame
At 24-hours (following treatment-1)
Title
Changes in 'Profile of Mood States' scores
Description
Monitoring daily mood changes using the Profile of Mood States (POMS) a validated 'self-report' psychological diagnostic containing 65 emotions or 'mood states' to determine the pattern of treatment response Patients rank their current mood states using a scale of 'not-at-all', 'a-little', 'moderately', 'quite-a-lot', 'extremely'. Responses are scored to calculated the Total Mood Disturbance (TMD): TMD = (tension + depression + anger + fatigue + confusion) - Vigor
Time Frame
Up to 1-week (following treatment-1)
Title
Sustainability of treatment response
Description
Determine sustained response and remission following study treatments (nitrous vs placebo) using Hamilton Depression Rating Scale-21 (HDRS-21) score. The HDRS-21 is an interview-based psychiatric diagnostic used to evaluate depression severity. Scores are calculated by using the first 17 responses of this 21 item questionnaire. Higher scores are associated with more severe depression: 0 - 7 = Normal 8 - 13 = Mild Depression 14-18 = Moderate Depression 19 - 22 = Severe Depression > 23 = Very Severe Depression Max score = 52
Time Frame
Over 7-weeks (length of study participation).
Title
Treatment dose response comparison
Description
Compare dose response of 25% vs 50% nitrous oxide to establish whether the concentration is related to outcome. Determined with treatment-by-dose (group) interaction term in a logistic regression model to assess for statistical significance.
Time Frame
Over 7-weeks (length of study participation)
Title
Treatment cycle compliance
Description
Evaluate compliance to complete 4-cycle inhalation treatments of nitrous oxide vs placebo. Determined by ability, inability, or refusal to receive all 4-treatments of randomized inhalation sessions (nitrous oxide vs placebo).
Time Frame
Over 4-weeks (weekly treatment sessions)
Title
Changes in Computerize Adaptive Testing - Mental Health (CAT-MH) 'depression' scores
Description
This CAT-MH is a validated self-reporting diagnostic that adaptively selects a small optimal set of items from a large bank of approximately 1,500 items, targeted to individuals current or historical level of severity and likelihood of 'depression'. Generated scores include severity and liklihood percentile: - depression = (%) normal, mild, moderate, severe
Time Frame
Over 7-weeks (length of study participation) from Baseline
Title
Changes in Computerize Adaptive Testing - Mental Health (CAT-MH) 'anxiety' scores
Description
This CAT-MH is a validated self-reporting diagnostic that adaptively selects a small optimal set of items from a large bank of approximately 1,500 items, targeted to individuals current or historical level of severity and likelihood of 'anxiety'. Generated scores include severity and liklihood percentile: - anxiety = (%) normal, mild, moderate, severe
Time Frame
Over 7-weeks (length of study participation) from Baseline
Title
Changes in Computerize Adaptive Testing - Mental Health (CAT-MH) 'suicide' scores
Description
This CAT-MH is a validated self-reporting diagnostic that adaptively selects a small optimal set of items from a large bank of approximately 1,500 items, targeted to individuals current or historical level of severity and likelihood of 'suicide'. Generated scores include severity and liklihood percentile: - suicide = (%) low, intermediate, high
Time Frame
Over 7-weeks (length of study participation) from Baseline
Title
Suicidal ideation tracking
Description
Suicidal ideation will be be tracked using the Sheehan Suicidality Tracking Scale (S-STS), a validated self-report diagnostic tool designed to assess and monitor suicidality. The standard S-STS consists of 14 core questions related to suicidality phenomena and is designed for use in clinical research studies and in clinical settings. Scores are summed based on individual responses 'not-at-all = 0', 'a little = 1', 'moderately = 2', 'very = 3', 'extremely = 4', to generate a summated score (total score), individual factor scores for suicidal ideation, suicidal intent, suicidal planning, suicidal behavior, and non-suicidal self-injury. All results are monitored in real time by a trained psychiatry (MD) rater.
Time Frame
Over 7-weeks (length of study participation) from Baseline
Title
Visual Analog Scale (VAS)
Description
The VAS is a unidimensional measure of pain intensity and use in the field of psychology to measure 'well-being'. Patients mark on a line the point that they feel represents their perception of their current state, with the score determined by measuring in millimetres from the left hand end of the line to the point that the patient marks. The range of score from 0-100 mm and represent: no pain (0-4 mm), mild pain(5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm).
Time Frame
At Baseline (Prior to treatment-1)
Title
Treatment remission
Description
Treatment remission (HDRS-21 ≤7 points) to nitrous oxide vs. placebo will be measured.
Time Frame
At 24-hours (following treatment-1)
Other Pre-specified Outcome Measures:
Title
Adverse Events
Description
Psychiatric AEs, such as new suicidal ideation and psychotic symptoms; AEs such as nausea and vomiting; or any other AEs determined probably, possibly, or unrelated to the study intervention. Study patient safety is monitored by the investigators (MD) with experience in critical care anesthesia, and psychiatry, as well as an experienced clinical research team responsible for monitoring and reporting events.
Time Frame
Over 7-weeks (length of study participation).

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adult (≥18 years, both sexes) DSM-5 criteria for MDD without psychosis, as determined using a structured clinical interview [Mini International Neuropsychiatric Interview], MDD, defined by a pre-treatment score >16 on the HDRS-21 scale and meeting DSM-5 for MDD Exclusion Criteria: A current or past history of bipolar disorder, schizophrenia, or schizoaffective disorder. Current obsessive-compulsive disorder, panic disorder, or documented Axis II diagnoses Active suicidal intention, as determined by clinical interview assessment tool (Sheehan-STS) and clinical examination Active or recent (<12 months) substance use disorder; excluding nicotine Administration of NMDA-antagonists (e.g., ketamine) in previous 3 months Ongoing treatment with ECT Presence of acute medical illness that could interfere with study participation, including significant pulmonary disease Pregnancy or breastfeeding Any contraindications to the use of nitrous oxide (e.g., pneumothorax, middle ear occlusion, elevated intracranial pressure, chronic cobalamin or folate deficiency unless treated with folic acid or vitamin B12).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Clinical Trials Manager
Phone
773-834-5778
Email
fbrown@dacc.uchicago.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Nagele, MD, MSc
Organizational Affiliation
University of Chicago, Department of Anesthesia and Critical Care
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Paul Myles, MD
Organizational Affiliation
The Alfred Hospital, Department of Anesthesiology and Perioperative Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Chicago Medicine
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Clinical Trials Manager
Phone
773-834-5778
Email
fbrown@dacc.uchicago.edu
First Name & Middle Initial & Last Name & Degree
Peter Nagele, MD, MSc
First Name & Middle Initial & Last Name & Degree
Royce Lee, MD
Facility Name
The Alfred Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3004
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Research Manager
Phone
03 90762651
Email
S.Wallace@alfred.org.au
First Name & Middle Initial & Last Name & Degree
Paul Myles, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
17132052
Citation
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442. doi: 10.1371/journal.pmed.0030442.
Results Reference
background
PubMed Identifier
27784055
Citation
Conway CR, George MS, Sackeim HA. Toward an Evidence-Based, Operational Definition of Treatment-Resistant Depression: When Enough Is Enough. JAMA Psychiatry. 2017 Jan 1;74(1):9-10. doi: 10.1001/jamapsychiatry.2016.2586. No abstract available.
Results Reference
background
PubMed Identifier
24314926
Citation
McIntyre RS, Filteau MJ, Martin L, Patry S, Carvalho A, Cha DS, Barakat M, Miguelez M. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014 Mar;156:1-7. doi: 10.1016/j.jad.2013.10.043. Epub 2013 Nov 15.
Results Reference
background
PubMed Identifier
22236505
Citation
Schlaepfer TE, Agren H, Monteleone P, Gasto C, Pitchot W, Rouillon F, Nutt DJ, Kasper S. The hidden third: improving outcome in treatment-resistant depression. J Psychopharmacol. 2012 May;26(5):587-602. doi: 10.1177/0269881111431748. Epub 2012 Jan 11.
Results Reference
background
PubMed Identifier
11480879
Citation
Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62 Suppl 16:10-7.
Results Reference
background
PubMed Identifier
27046518
Citation
Kim YK, Na KS. Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Oct 3;70:117-26. doi: 10.1016/j.pnpbp.2016.03.009. Epub 2016 Apr 1.
Results Reference
background
PubMed Identifier
27449797
Citation
Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC, Zarate CA Jr. Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. Biol Psychiatry. 2017 May 15;81(10):886-897. doi: 10.1016/j.biopsych.2016.05.005. Epub 2016 May 12.
Results Reference
background
PubMed Identifier
27409299
Citation
Palucha-Poniewiera A, Pilc A. Glutamate-Based Drug Discovery for Novel Antidepressants. Expert Opin Drug Discov. 2016 Sep;11(9):873-83. doi: 10.1080/17460441.2016.1213234. Epub 2016 Aug 2.
Results Reference
background
PubMed Identifier
26854424
Citation
Gerhard DM, Wohleb ES, Duman RS. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. Drug Discov Today. 2016 Mar;21(3):454-64. doi: 10.1016/j.drudis.2016.01.016. Epub 2016 Feb 6.
Results Reference
background
PubMed Identifier
21677641
Citation
Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011 Jun 15;475(7354):91-5. doi: 10.1038/nature10130.
Results Reference
background
PubMed Identifier
26415966
Citation
McCloud TL, Caddy C, Jochim J, Rendell JM, Diamond PR, Shuttleworth C, Brett D, Amit BH, McShane R, Hamadi L, Hawton K, Cipriani A. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev. 2015 Sep 29;(9):CD011611. doi: 10.1002/14651858.CD011611.pub2.
Results Reference
background
PubMed Identifier
23661785
Citation
Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK. Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry. 2013 Aug;47(8):710-27. doi: 10.1177/0004867413486842. Epub 2013 May 9.
Results Reference
background
PubMed Identifier
26478208
Citation
Hu YD, Xiang YT, Fang JX, Zu S, Sha S, Shi H, Ungvari GS, Correll CU, Chiu HF, Xue Y, Tian TF, Wu AS, Ma X, Wang G. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med. 2016 Feb;46(3):623-35. doi: 10.1017/S0033291715002159. Epub 2015 Oct 19.
Results Reference
background
PubMed Identifier
25954495
Citation
Iadarola ND, Niciu MJ, Richards EM, Vande Voort JL, Ballard ED, Lundin NB, Nugent AC, Machado-Vieira R, Zarate CA Jr. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015 May;6(3):97-114. doi: 10.1177/2040622315579059. Erratum In: Ther Adv Chronic Dis. 2016 May;7(3):184.
Results Reference
background
PubMed Identifier
25462290
Citation
Kavalali ET, Monteggia LM. How does ketamine elicit a rapid antidepressant response? Curr Opin Pharmacol. 2015 Feb;20:35-9. doi: 10.1016/j.coph.2014.11.005. Epub 2014 Nov 25.
Results Reference
background
PubMed Identifier
24688759
Citation
Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol. 2014 Apr;4(2):75-99. doi: 10.1177/2045125313507739.
Results Reference
background
PubMed Identifier
26919405
Citation
Lenze EJ, Farber NB, Kharasch E, Schweiger J, Yingling M, Olney J, Newcomer JW. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial. World J Biol Psychiatry. 2016 Apr;17(3):230-8. doi: 10.3109/15622975.2016.1142607. Epub 2016 Feb 26.
Results Reference
background
PubMed Identifier
17006715
Citation
Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl). 2006 Nov;188(4):408-24. doi: 10.1007/s00213-006-0572-3. Epub 2006 Sep 28.
Results Reference
background
PubMed Identifier
21777321
Citation
Morgan CJ, Curran HV; Independent Scientific Committee on Drugs. Ketamine use: a review. Addiction. 2012 Jan;107(1):27-38. doi: 10.1111/j.1360-0443.2011.03576.x. Epub 2011 Jul 22.
Results Reference
background
PubMed Identifier
18813051
Citation
Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology. 2008 Oct;109(4):707-22. doi: 10.1097/ALN.0b013e3181870a17.
Results Reference
background
PubMed Identifier
15159532
Citation
Nagele P, Metz LB, Crowder CM. Nitrous oxide (N(2)O) requires the N-methyl-D-aspartate receptor for its action in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8791-6. doi: 10.1073/pnas.0402825101. Epub 2004 May 24.
Results Reference
background
PubMed Identifier
26696909
Citation
Zorumski CF, Nagele P, Mennerick S, Conway CR. Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy. Front Psychiatry. 2015 Dec 9;6:172. doi: 10.3389/fpsyt.2015.00172. eCollection 2015.
Results Reference
background
PubMed Identifier
12448895
Citation
Certosimo F, Walton M, Hartzell D, Farris J. Clinical evaluation of the efficacy of three nitrous oxide scavenging units during dental treatment. Gen Dent. 2002 Sep-Oct;50(5):430-5.
Results Reference
background
PubMed Identifier
25142708
Citation
Myles PS, Leslie K, Chan MT, Forbes A, Peyton PJ, Paech MJ, Beattie WS, Sessler DI, Devereaux PJ, Silbert B, Schricker T, Wallace S; ANZCA Trials Group for the ENIGMA-II investigators. The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): a randomised, single-blind trial. Lancet. 2014 Oct 18;384(9952):1446-54. doi: 10.1016/S0140-6736(14)60893-X.
Results Reference
background
PubMed Identifier
17667565
Citation
Myles PS, Leslie K, Chan MT, Forbes A, Paech MJ, Peyton P, Silbert BS, Pascoe E; ENIGMA Trial Group. Avoidance of nitrous oxide for patients undergoing major surgery: a randomized controlled trial. Anesthesiology. 2007 Aug;107(2):221-31. doi: 10.1097/01.anes.0000270723.30772.da.
Results Reference
background
PubMed Identifier
23856660
Citation
Nagele P, Brown F, Francis A, Scott MG, Gage BF, Miller JP; VINO Study Team. Influence of nitrous oxide anesthesia, B-vitamins, and MTHFR gene polymorphisms on perioperative cardiac events: the vitamins in nitrous oxide (VINO) randomized trial. Anesthesiology. 2013 Jul;119(1):19-28. doi: 10.1097/ALN.0b013e31829761e3.
Results Reference
background
PubMed Identifier
8733798
Citation
Snaith RP. Present use of the Hamilton Depression Rating Scale: observation on method of assessment in research of depressive disorders. Br J Psychiatry. 1996 May;168(5):594-7. doi: 10.1192/bjp.168.5.594.
Results Reference
background
PubMed Identifier
27525966
Citation
Kyle PR, Lemming OM, Timmerby N, Sondergaard S, Andreasson K, Bech P. The Validity of the Different Versions of the Hamilton Depression Scale in Separating Remission Rates of Placebo and Antidepressants in Clinical Trials of Major Depression. J Clin Psychopharmacol. 2016 Oct;36(5):453-6. doi: 10.1097/JCP.0000000000000557.
Results Reference
background
PubMed Identifier
17873700
Citation
Furukawa TA, Akechi T, Azuma H, Okuyama T, Higuchi T. Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression. J Clin Psychopharmacol. 2007 Oct;27(5):531-4. doi: 10.1097/JCP.0b013e31814f30b1. No abstract available.
Results Reference
background
PubMed Identifier
25919835
Citation
Ueno F, Nakajima S, Suzuki T, Abe T, Sato Y, Mimura M, Uchida H. Whether to increase or maintain dosage of mirtazapine in early nonimprovers with depression. J Clin Psychiatry. 2015 Apr;76(4):434-9. doi: 10.4088/JCP.14m09201.
Results Reference
background
PubMed Identifier
25655160
Citation
Levkovitz Y, Isserles M, Padberg F, Lisanby SH, Bystritsky A, Xia G, Tendler A, Daskalakis ZJ, Winston JL, Dannon P, Hafez HM, Reti IM, Morales OG, Schlaepfer TE, Hollander E, Berman JA, Husain MM, Sofer U, Stein A, Adler S, Deutsch L, Deutsch F, Roth Y, George MS, Zangen A. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015 Feb;14(1):64-73. doi: 10.1002/wps.20199.
Results Reference
background
PubMed Identifier
23357658
Citation
Leucht S, Fennema H, Engel R, Kaspers-Janssen M, Lepping P, Szegedi A. What does the HAMD mean? J Affect Disord. 2013 Jun;148(2-3):243-8. doi: 10.1016/j.jad.2012.12.001. Epub 2013 Jan 26.
Results Reference
background
PubMed Identifier
23117634
Citation
Gibbons RD, Weiss DJ, Pilkonis PA, Frank E, Moore T, Kim JB, Kupfer DJ. Development of a computerized adaptive test for depression. Arch Gen Psychiatry. 2012 Nov;69(11):1104-12. doi: 10.1001/archgenpsychiatry.2012.14. Erratum In: Arch Gen Psychiatry. 2013 Jan;70(1):30.
Results Reference
background
PubMed Identifier
28493655
Citation
Gibbons RD, Kupfer D, Frank E, Moore T, Beiser DG, Boudreaux ED. Development of a Computerized Adaptive Test Suicide Scale-The CAT-SS. J Clin Psychiatry. 2017 Nov/Dec;78(9):1376-1382. doi: 10.4088/JCP.16m10922.
Results Reference
background
PubMed Identifier
25577164
Citation
Nagele P, Duma A, Kopec M, Gebara MA, Parsoei A, Walker M, Janski A, Panagopoulos VN, Cristancho P, Miller JP, Zorumski CF, Conway CR. Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial. Biol Psychiatry. 2015 Jul 1;78(1):10-18. doi: 10.1016/j.biopsych.2014.11.016. Epub 2014 Dec 9.
Results Reference
background
PubMed Identifier
24449311
Citation
Djulbegovic B, Hozo I, Ioannidis JP. Improving the drug development process: more not less randomized trials. JAMA. 2014 Jan 22-29;311(4):355-6. doi: 10.1001/jama.2013.283742. No abstract available.
Results Reference
background

Learn more about this trial

Antidepressant Effects of Nitrous Oxide

We'll reach out to this number within 24 hrs